ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ponticiello, A
Right arrow Articles by Sanduzzi, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ponticiello, A
Right arrow Articles by Sanduzzi, A
Eur Respir J 2000; 15: 547-552
Copyright © ERS Journals Ltd 2000

Original Articles

P53 immunohistochemistry can identify bronchial dysplastic lesions proceeding to lung cancer: a prospective study

A Ponticiello, E Barra, U Giani, M Bocchino, and A Sanduzzi

Dysplasia is an important step in bronchial carcinogenesis and smokers present more dysplastic lesions than nonsmokers. These lesions not always lead to malignancy, so there is a need for additional, preferentially objective, diagnostic markers. To verify whether immunohistochemical overexpression of p53 protein in dysplastic areas could be a predictive marker of the development of lung cancer, we investigated p53 overexpression in 22 bronchial dysplastic lesions obtained by fibrebronchoscopy from heavy smokers who were not diagnosed as having lung cancer and were followed for a 4-yr period. Nine (41%) lesions showed p53-positivity. Seven lung cancers (78%), mostly squamous cell carcinomas, were detected within the follow-up in these patients and 3 in 13 (23%) patients with p53-negative lesions. Lung cancer occurred in all seven patients with dysplastic lesions showing >10% p53 positive nuclei. The positive predictive value of p53 immunostaining for lung cancer was 78%. The negative predictive value of p53 was 77%. p53 staining was not detected in squamous metaplasia lesions without atypia and in normal bronchial epithelium. Our findings provide evidence that p53-overexpression in bronchial dysplastic areas may be a clinically useful marker for identifying patients proceeding to, at least, squamous cell carcinoma and, in addition, may facilitate the detection of occult tumours.


This article has been cited by other articles:


Home page
 Cancer Prevention ResearchHome page
H. Kadara, L. Lacroix, C. Behrens, L. Solis, X. Gu, J. J. Lee, E. Tahara, D. Lotan, W. K. Hong, I. I. Wistuba, et al.
Identification of Gene Signatures and Molecular Markers for Human Lung Cancer Prognosis using an In vitro Lung Carcinogenesis System
Cancer Prevention Research, August 1, 2009; 2(8): 702 - 711.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
K Haussinger, H Becker, F Stanzel, A Kreuzer, B Schmidt, J Strausz, S Cavaliere, F Herth, M Kohlhaufl, K-M Muller, et al.
Autofluorescence bronchoscopy with white light bronchoscopy compared with white light bronchoscopy alone for the detection of precancerous lesions: a European randomised controlled multicentre trial
Thorax, June 1, 2005; 60(6): 496 - 503.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Lantuejoul, J. C. Soria, L. Morat, P. Lorimier, D. Moro-Sibilot, L. Sabatier, C. Brambilla, and E. Brambilla
Telomere Shortening and Telomerase Reverse Transcriptase Expression in Preinvasive Bronchial Lesions
Clin. Cancer Res., March 1, 2005; 11(5): 2074 - 2082.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Jeanmart, S. Lantuejoul, F. Fievet, D. Moro, N. Sturm, C. Brambilla, and E. Brambilla
Value of Immunohistochemical Markers in Preinvasive Bronchial Lesions in Risk Assessment of Lung Cancer
Clin. Cancer Res., June 1, 2003; 9(6): 2195 - 2203.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
A K Banerjee, P H Rabbitts, and J George
Lung cancer * 3: Fluorescence bronchoscopy: clinical dilemmas and research opportunities
Thorax, March 1, 2003; 58(3): 266 - 271.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
C. Brambilla, F. Fievet, M. Jeanmart, F. de Fraipont, S. Lantuejoul, V. Frappat, G. Ferretti, P.Y. Brichon, and D. Moro-Sibilot
Early detection of lung cancer: role of biomarkers
Eur. Respir. J., January 1, 2003; 21(39_suppl): 36S - 44s.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the European Respiratory Society.